In this study, the impact of advancements in surgical technique and systemic therapy for stage II and III rectal cancers was assessed via a comparison of outcomes after neoadjuvant chemoradiotherapy followed by definitive resection with those for neoadjuvant multiagent chemotherapy without radiation therapy.
Poor compliance to NCCN guidelines for adjuvant chemotherapy appears to be associated with poorer overall survival.
Use of neoadjuvant chemoradiotherapy (NACRT) before surgery among patients with rectal cancer has substantially increased over the past decade.
Nearly 50% of patients with stage II/III rectal cancer achieve a complete clinical response via neoadjuvant chemoradiation.
A new study indicates that patient travel distance to an appropriate treatment facility can impact whether radiation therapy is received.
Patients with rectal cancer reported aerobic exercise during neoadjuvant chemoradiotherapy to be more enjoyable and less difficult.
No difference in local efficacy was found between two treatment regimens for colorectal cancer: short-course (5-day) radiation followed by consolidation chemotherapy before surgery and standard 5-week chemoradiation.
Patients who had the procedure eight weeks after chemo and radiation therapy demonstrated the best survival rates.
Baseline dietary glutamic acid intake is associated with a lower risk for developing colorectal cancer, particularly in people who are not overweight.
Compared with open surgery, laparascopic surgery fails to improve outcomes for patients with stage 2 or 3 rectal cancer.
New study data associates the resection of colorectal cancer (CRC) liver metastases with greater risk of postoperative mortality among elderly patients.
Patients with colorectal cancer that is detected during a colonoscopy screening are more likely to survive to longer than patients who are not diagnosed until they have symptoms.
mFOLFOX6 administered concurrently with radiation therapy resulted in a higher pathological complete response in rectal cancer.
Patients with rectal cancer that experienced a complete response had similar 4-year survival rates regardless of whether they had immediate surgery or pursued a watch-and-wait approach.
A review of top clinical guidelines for rectal cancer shows a variety of treatment recommendations.
A new phase II study finds that if chemotherapy is offered before radiation and surgery, more patients will be able to tolerate it and receive a full regimen of treatment.
Long-term results of an EORTC trial show that 5- fluorouracil (FU)-based adjuvant chemotherapy after preoperative chemoradiotherapy for patients with cT3-resectable T4 M0 rectal cancer does not improve survival or disease-free survival.
Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.
Early end-of-life talks are associated with less aggressive care and greater use of hospice services when patients do reach their final days.
News from the FDA on bosutinib (Bosulif), ziv-aflibercept (Zaltrap), and everolimus oral suspension tablets (Afinitor Disperz).
Two of three main recommendations for colonoscopy surveillance are now supported by stronger evidence than they were in 2006.
I knew Sam's joking was not a sign of joy or happiness but his way of coping, maybe the only way he knew how.
No significant differences in rates of local, distant recurrence; overall survival; or late toxicity.
News about pertuzumab injection (Perjeta); ondansetron (Zofran); carfilzomib (Kyprolis); Therascreen KRAS RGQ PCR Kit; Prostate Health Index (phi); and Prepopik
CT colonography can accurately detect adenomas 10 mm or larger in patients who did not undergo laxative-induced bowel cleansing before the procedure.
Childhood cancer survivors may need earlier colorectal cancer screening, especially if abdominal radiation was part of their treatment.
CT colonography accurately detects cancer and precancerous polyps in persons aged 65 years and older.
Dabrafenib, which targets a genetic mutation that is active in half of melanoma cases, substantially and safely shrank metastatic tumors.
Overall US cancer death rates have continued to decline since the early 1990s, but excess weight and lack of sufficient activity contribute to the increased incidence of many cancers.
One-third of outpatients with breast, prostate, colon/rectum, or lung cancer were receiving insufficient pain treatment, particularly minorities.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Immunotherapy and the Future of Prostate Cancer Treatment
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Use of Checkpoint Inhibitors in Urothelial Carcinoma
- Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Colorectal Cancer Risk Higher With Poor Metabolic Health vs Increased Weight
- Best Approach to Infection and Tumor Treatment: Contain or Eliminate?
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|